Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Western Union Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Western Union Co trades at $7.05 (market cap $2.19B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.3× Western Union Co's market cap, and Western Union Co pays a 13.37% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WU | |
|---|---|---|
Market Cap | $9.39B | $2.19B |
Sector | Health | Technology |
52-Week High | $354.54 | $10.28 |
52-Week Low | $241.71 | $6.36 |
Enterprise Value | $9.14B | $2.10B |
Dividend Yield | — | 13.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Western Union (WU) trades at $7.08, down 1.12% today, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Valuation ratios appear attractive with a P/E of 5.71 and P/S of 0.56, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company maintains a strong dividend yield, paying $0.24 quarterly, and recently launched Stablecard with Rain to expand digital services.
The outlook is cautious due to earnings volatility and competitive pressures in money transfers. Opportunities include cost management and digital growth, but risks from declining retail performance and high debt levels persist. Analyst consensus is mixed with a $7.14 price target, reflecting uncertainty over turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
